Activin A–Induced Cachectic Wasting Is Attenuated by Systemic Delivery of Its Cognate Propeptide in Male Mice
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
In cancer, elevated activin levels promote cachectic wasting of muscle, irrespective of tumor progression. In excess, activins A and B use the myostatin signaling pathway in muscle, triggering a decrease in protein synthesis and an increase in protein degradation, which ultimately leads to atrophy. Recently, we demonstrated that local delivery of engineered activin and myostatin propeptides (natural inhibitors of these growth factors) could induce profound muscle hypertrophy in healthy mice. Additionally, the expression of these propeptides effectively attenuated localized muscle wasting in models of dystrophy and cancer cachexia. In this study, we examined whether a systemically administered recombinant propeptide could reverse activin A–induced cachectic wasting in mice. Chinese hamster ovary cells stably expressing activin A were transplanted into the quadriceps of nude mice and caused an 85-fold increase in circulating activin A levels within 12 days. Elevated activin A induced a rapid reduction in body mass (−16%) and lean mass (−10%). In agreement with previous findings, we demonstrated that adeno-associated virus–mediated delivery of activin propeptide to the tibialis anterior muscle blocked activin-induced wasting. In addition, despite massively elevated levels of activin A in this model, systemic delivery of the propeptide significantly reduced activin-induced changes in lean and body mass. Specifically, recombinant propeptide reversed activin-induced wasting of skeletal muscle, heart, liver, and kidneys. This is the first study to demonstrate that systemic administration of recombinant propeptide therapy effectively attenuates tumor-derived activin A insult in multiple tissues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“similar to effects seen when using a dominant-negative type II receptor or pro-domains of GDF8 and activins22,26,27.”
From GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates (2025) · cites this paper as [27]
In the citing paper
“We and others have previously demonstrated that growth differentiation factor-8 (GDF8; also known as myostatin) and activin A (ActA) are the two major ligands mediating the muscle-minimization actions of ActRIIA/B receptors22,26–30.”
From GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates (2025) · cites this paper as [27]
Citations
Cites
Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways
Fearon, K. C. H., Glass, D. J., & Guttridge, D. C. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.06.011 · Cited by 1,205
Tisdale, M. J. (2009) · Physiological Reviews · doi:10.1152/physrev.00016.2008 · Cited by 1,192
Latent TGF-β structure and activation
Shi, M., Zhu, J., Wang, R., Chen, X., Mi, L., Walz, T., & Springer, T. A. (2011) · Nature · doi:10.1038/nature10152 · Cited by 1,013
Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival
Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W. S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.011 · Cited by 940
Induction of Cachexia in Mice by Systemically Administered Myostatin
Zimmers, T. A., Davies, M. V., Koniaris, L. G., Haynes, P., Esquela, A. F., Tomkinson, K. N., McPherron, A. C., Wolfman, N. M., & Lee, S.-J. (2002) · Science · doi:10.1126/science.1069525 · Cited by 907 · cited 7×
“2426 Walton et al Inhibiting Activin A–-Induced Cachexia Endocrinology, October 2019, 160(10):2417–2426”
BackgroundInfluentialA Switch from White to Brown Fat Increases Energy Expenditure in Cancer-Associated Cachexia
Petruzzelli, M., Schweiger, M., Schreiber, R., Campos-Olivas, R., Tsoli, M., Allen, J., Swarbrick, M., Rose-John, S., Rincon, M., Robertson, G., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.06.011 · Cited by 750
Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1
Johnen, H., Lin, S., Kuffner, T., Brown, D. A., Tsai, V. W.-W., Bauskin, A. R., Wu, L., Pankhurst, G., Jiang, L., Junankar, S., et al. (2007) · Nature Medicine · doi:10.1038/nm1677 · Cited by 612
Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis
Walton, K. L., Johnson, K. E., & Harrison, C. A. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00461 · Cited by 543 · cited 1×
“activins are known to cause fibrosis in the liver and kidneys (34), propeptide therapy may be antifibrotic in these tissues.”
BackgroundSelf-citationDual role of the Smad4/DPC4 tumor suppressor in TGFβ-inducible transcriptional complexes
Liu, F., Pouponnot, C., & Massagué, J. (1997) · Genes & Development · doi:10.1101/gad.11.23.3157 · Cited by 445 · cited 1×
“At 24 hours after plating, cells were transfected with the Smad2/3-responsive A3-luciferase reporter construct and FAST2 transcription factor (26), using Lipofectamine 2000 (Thermo Fisher Scientific).”
MethodMechanisms of metabolic dysfunction in cancer-associated cachexia
Petruzzelli, M., & Wagner, E. F. (2016) · Genes & Development · doi:10.1101/gad.276733.115 · Cited by 340
Knight, P. G., Muttukrishna, S., & Groome, N. P. (1996) · Journal of Endocrinology · doi:10.1677/joe.0.1480267 · Cited by 256 · cited 2×
“Surviving cell colonies were expanded and screened for activin A expression by ELISA, as previously described (24).”
MethodEfficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6
Blankinship, M. J., Gregorevic, P., Allen, J. M., Harper, S. Q., Harper, H., Halbert, C. L., Miller, D. A., & Chamberlain, J. S. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.016 · Cited by 251
Self-citationA Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy
Mendell, J. R., Sahenk, Z., Malik, V., Gomez, A. M., Flanigan, K. M., Lowes, L. P., Alfano, L. N., Berry, K., Meadows, E., Lewis, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.200 · Cited by 246 · cited 1×
“Although effective at increasing muscle mass, these molecules are prone to offtarget effects as a result of their capacities to bind multiple TGF-b ligands (29, 31).”
BackgroundCampbell, C., McMillan, H. J., Mah, J. K., Tarnopolsky, M., Selby, K., McClure, T., Wilson, D. M., Sherman, M. L., Escolar, D., & Attie, K. M. (2017) · Muscle & Nerve · doi:10.1002/mus.25268 · Cited by 240 · cited 1×
“Although effective at increasing muscle mass, these molecules are prone to offtarget effects as a result of their capacities to bind multiple TGF-b ligands (29, 31).”
BackgroundLerner, L., Hayes, T. G., Tao, N., Krieger, B., Feng, B., Wu, Z., Nicoletti, R., Chiu, M. I., Gyuris, J., & Garcia, J. M. (2015) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12033 · Cited by 208 · cited 2×
“(12) also showed that activin A is associated with weight loss, decreased muscle mass and strength, and poor survival in patients with cancer, and we have found that activin A expression is increased in many human cancer cell lines, particularly those that are highly malignant (8).”
BackgroundElevated expression of activins promotes muscle wasting and cachexia
Chen, J. L., Walton, K. L., Winbanks, C. E., Murphy, K. T., Thomson, R. E., Makanji, Y., Qian, H., Lynch, G. S., Harrison, C. A., & Gregorevic, P. (2014) · The FASEB Journal · doi:10.1096/fj.13-245894 · Cited by 202
Self-citationElevated Levels of Activin A in Heart Failure: Potential Role in Myocardial Remodeling
Yndestad, A., Ueland, T., Øie, E., Florholmen, G., Halvorsen, B., Attramadal, H., Simonsen, S., Frøland, S. S., Gullestad, L., Christensen, G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000120704.97934.41 · Cited by 180 · cited 1×
“As activin A levels are frequently elevated in cancer (12, 13), heart failure (14), sepsis (15), and lung disease (16), concerted efforts are now directed toward the development of antiactivin therapies to limit muscle wasting in these conditions (17, 18).”
BackgroundA single ascending‐dose study of muscle regulator ace‐031 in healthy volunteers
Attie, K. M., Borgstein, N. G., Yang, Y., Condon, C. H., Wilson, D. M., Pearsall, A. E., Kumar, R., Willins, D. A., Seehra, J. S., & Sherman, M. L. (2013) · Muscle & Nerve · doi:10.1002/mus.23539 · Cited by 176
Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem
Tsoli, M., & Robertson, G. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.10.006 · Cited by 170 · cited 1×
“2 million people globally in 2012) (2).”
Induction of Apoptosis in the Murine Liver With Recombinant Human Activin A
Hully, J. R., Chang, L., Schwall, R. H., Widmer, R. H., Terrell, T. G., & Gillett, N. A. (1994) · Hepatology · doi:10.1002/hep.1840200413 · Cited by 118 · cited 1×
“blocking activin-mediated apoptosis of hepatocytes and the resulting loss of liver mass (33).”
BackgroundChen, J. L., Walton, K. L., Hagg, A., Colgan, T. D., Johnson, K., Qian, H., Gregorevic, P., & Harrison, C. A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620013114 · Cited by 116 · cited 3×
“However, we have shown that forced covalent linkage of two propeptide chains dramatically increases affinity for mature activin A, such that the modified propeptide can be used to block activin activity in vitro and in vivo (18, 19).”
BackgroundSelf-citationSupraphysiological levels of GDF 11 induce striated muscle atrophy
Hammers, D. W., Merscham‐Banda, M., Hsiao, J. Y., Engst, S., Hartman, J. J., & Sweeney, H. L. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607231 · Cited by 115 · cited 1×
“causes systemic wasting (10, 28) and suggest that ele-”
BackgroundStructure of bone morphogenetic protein 9 procomplex
Mi, L.-Z., Brown, C. T., Gao, Y., Tian, Y., Le, V. Q., Walz, T., & Springer, T. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501303112 · Cited by 111
Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes
Mendell, J. R., Sahenk, Z., Al-Zaidy, S., Rodino-Klapac, L. R., Lowes, L. P., Alfano, L. N., Berry, K., Miller, N., Yalvac, M., Dvorchik, I., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.015 · Cited by 109 · cited 1×
“Additionally, it would be valuable to examine the propeptide in fibrotic disease, as activin A has established profibrotic activity (30).”
BackgroundMichel, U., Ebert, S., Phillips, D., & Nau, R. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480559 · Cited by 95 · cited 1×
“As activin A levels are frequently elevated in cancer (12, 13), heart failure (14), sepsis (15), and lung disease (16), concerted efforts are now directed toward the development of antiactivin therapies to limit muscle wasting in these conditions (17, 18).”
BackgroundStructure and activation of pro-activin A
Wang, X., Fischer, G., & Hyvönen, M. (2016) · Nature Communications · doi:10.1038/ncomms12052 · Cited by 93
The TGF-β Signalling Network in Muscle Development, Adaptation and Disease
Chen, J. L., Colgan, T. D., Walton, K. L., Gregorevic, P., & Harrison, C. A. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-27511-6_5 · Cited by 88 · cited 1×
“protein synthesis, increases protein degradation, and, thereby, reduces muscle mass (11).”
BackgroundSelf-citationDifferential Effects of IL6 and Activin A in the Development of Cancer-Associated Cachexia
Chen, J. L., Walton, K. L., Qian, H., Colgan, T. D., Hagg, A., Watt, M. J., Harrison, C. A., & Gregorevic, P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3152 · Cited by 87
Self-citationCirculating Activin A predicts survival in cancer patients
Loumaye, A., de Barsy, M., Nachit, M., Lause, P., van Maanen, A., Trefois, P., Gruson, D., & Thissen, J. (2017) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12209 · Cited by 79 · cited 1×
“As activin A levels are frequently elevated in cancer (12, 13), heart failure (14), sepsis (15), and lung disease (16), concerted efforts are now directed toward the development of antiactivin therapies to limit muscle wasting in these conditions (17, 18).”
BackgroundElevated levels of activin A in clinical and experimental pulmonary hypertension
Yndestad, A., Larsen, K., Øie, E., Ueland, T., Smith, C., Halvorsen, B. L., Sjaastad, I., Skjønsberg, O. H., Pedersen, T. M., Anfinsen, O.-G., et al. (2009) · Journal of Applied Physiology · doi:10.1152/japplphysiol.90719.2008 · Cited by 78 · cited 1×
“As activin A levels are frequently elevated in cancer (12, 13), heart failure (14), sepsis (15), and lung disease (16), concerted efforts are now directed toward the development of antiactivin therapies to limit muscle wasting in these conditions (17, 18).”
BackgroundLok, C. (2015) · Nature · doi:10.1038/528182a · Cited by 63 · cited 1×
“Cachexia, referred to as “the last illness,” is a metabolic disorder that affects millions of people worldwide, including 80% of individuals with advanced cancer (1).”
BackgroundActivin A Binds to Perlecan through Its Pro-region That Has Heparin/Heparan Sulfate Binding Activity
Li, S., Shimono, C., Norioka, N., Nakano, I., Okubo, T., Yagi, Y., Hayashi, M., Sato, Y., Fujisaki, H., Hattori, S., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.177865 · Cited by 62 · cited 1×
“propeptide is likely attributed to its affinity for heparin sulfate proteoglycans (35), which are concentrated in the”
BackgroundDevelopment of Novel Activin-Targeted Therapeutics
Chen, J. L., Walton, K. L., Al-Musawi, S. L., Kelly, E. K., Qian, H., La, M., Lu, L., Lovrecz, G., Ziemann, M., Lazarus, R., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.221 · Cited by 54 · cited 10×
“However, we have shown that forced covalent linkage of two propeptide chains dramatically increases affinity for mature activin A, such that the modified propeptide can be used to block activin activity in vitro and in vivo (18, 19).”
BackgroundMethodSelf-citationGeneration of a Specific Activin Antagonist by Modification of the Activin A Propeptide
Makanji, Y., Walton, K. L., Chan, K. K. L., Gregorevic, P., Robertson, D. M., & Harrison, C. A. (2011) · Endocrinology · doi:10.1210/en.2011-1052 · Cited by 25 · cited 1×
“, soluble activin receptors), the activin A propeptide selectively inhibits activin A signaling (20) without disrupting the activities of related ligands: activin B, myostatin, or GDF11 (19).”
BackgroundSelf-citation
Cited by
Cachexia: A systemic consequence of progressive, unresolved disease
Ferrer, M., Anthony, T. G., Ayres, J. S., Biffi, G., Brown, J. C., Caan, B. J., Cespedes Feliciano, E. M., Coll, A. P., Dunne, R. F., Goncalves, M. D., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.028 · Cited by 260
Pathophysiological mechanisms leading to muscle loss in chronic kidney disease
Wang, X. H., Mitch, W. E., & Price, S. R. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00498-0 · Cited by 170
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Muscle-to-tumor crosstalk: The effect of exercise-induced myokine on cancer progression
Huang, Q., Wu, M., Wu, X., Zhang, Y., & Xia, Y. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188761 · Cited by 138
Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
Rodgers, B. D., & Ward, C. W. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab030 · Cited by 111
Metadata
- Authors
- Walton, K. L., Chen, J. L., Arnold, Q., Kelly, E., La, M., Lu, L., Lovrecz, G., Hagg, A., Colgan, T. D., Qian, H., Gregorevic, P., & Harrison, C. A.
- Affiliations
- Hudson Institute of Medical Research (AU)
- Baker Heart and Diabetes Institute (AU)
- Commonwealth Scientific and Industrial Research Organisation (AU)
- Corresponding author
- Gregorevic, Paul
- Harrison, Craig A
- ORCID
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2019-07-19
- Volume
- 160
- Issue
- 10
- Pages
- 2417-2426
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2965577218
- Semantic Scholar
- 1315370ebfd3e080c0d5fae7df6304c9088be79c
- Cited by
- 23
- References
- 34
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 5 · 2020: 4
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Health and Medical Research Council (1078907, 1046782)
- Cancer Council Victoria
- Victorian Cancer Agency (ECSG14014)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- activin A, cachexia, skeletal muscle atrophy, myostatin signaling, adeno-associated virus delivery, systemic administration, lean mass loss, muscle atrophy
- MeSH terms
- Animals, Cachexia, Cricetulus, Cricetinae, Kidney, Liver, Male, Myocardium, Organ Size, Peptides, CHO Cells, Muscle, Skeletal, Activins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.